- Home
- TEX vs AKRO Comparison
TEX vs AKRO Comparison
Compare TEX & AKRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TEX
- AKRO
- Stock Information
- Founded
- TEX 1933
- AKRO 2017
- Country
- TEX United States
- AKRO United States
- Employees
- TEX N/A
- AKRO N/A
- Industry
- TEX Construction/Ag Equipment/Trucks
- AKRO Biotechnology: Pharmaceutical Preparations
- Sector
- TEX Industrials
- AKRO Health Care
- Exchange
- TEX Nasdaq
- AKRO Nasdaq
- Market Cap
- TEX 3.3B
- AKRO 3.9B
- IPO Year
- TEX N/A
- AKRO 2019
- Fundamental
- Price
- TEX $50.28
- AKRO $49.38
- Analyst Decision
- TEX Buy
- AKRO Strong Buy
- Analyst Count
- TEX 9
- AKRO 7
- Target Price
- TEX $51.44
- AKRO $81.57
- AVG Volume (30 Days)
- TEX 793.4K
- AKRO 1.1M
- Earning Date
- TEX 07-31-2025
- AKRO 08-08-2025
- Dividend Yield
- TEX 1.35%
- AKRO N/A
- EPS Growth
- TEX N/A
- AKRO N/A
- EPS
- TEX 2.67
- AKRO N/A
- Revenue
- TEX $5,169,000,000.00
- AKRO N/A
- Revenue This Year
- TEX $4.84
- AKRO N/A
- Revenue Next Year
- TEX $4.33
- AKRO N/A
- P/E Ratio
- TEX $18.81
- AKRO N/A
- Revenue Growth
- TEX N/A
- AKRO N/A
- 52 Week Low
- TEX $31.53
- AKRO $21.34
- 52 Week High
- TEX $58.66
- AKRO $58.40
- Technical
- Relative Strength Index (RSI)
- TEX 51.73
- AKRO 47.31
- Support Level
- TEX $47.47
- AKRO $47.10
- Resistance Level
- TEX $52.62
- AKRO $50.19
- Average True Range (ATR)
- TEX 1.74
- AKRO 2.36
- MACD
- TEX 0.05
- AKRO 0.02
- Stochastic Oscillator
- TEX 54.56
- AKRO 51.14
About TEX Terex Corporation
Terex Corp is a manufacturer of materials processing machinery, waste and recycling solutions, mobile elevating work platforms (MEWPs), and equipment for the electric utility industry. The company designs builds, and supports products used in maintenance, manufacturing, energy, waste and recycling, minerals and materials management, construction, and the entertainment industry. The products are manufactured in North America, Europe, and Asia Pacific and sold all over the world. The company reports business in the following segments: (i) Materials Processing, (ii) Aerial Work Platforms, and (iii) Environmental Solutions Group.
About AKRO Akero Therapeutics Inc.
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis.